Recent advancements in the field of biomarkers have significantly enhanced the early diagnosis and prevention of gynaecological tumors, including cervical, endometrial, and ovarian cancers. These biomarkers are pivotal in the accurate, non-invasive detection of early-stage cancers, thereby facilitating timely therapeutic interventions while the disease is still manageable. Despite these strides, the diagnosis of gynaecological tumors often occurs at advanced stages, underscoring an urgent need for improved early detection methodologies.
The development and validation of new biomarker detection techniques hold promise for early identification of gynaecological malignancies, even at the precancerous stage. Early detection is crucial as it directly influences treatment efficacy and patient outcomes. Biomarkers such as hormone receptors, HER2, Ki-67, TP53, and BRCA1/BRCA2 have garnered significant research interest due to their prognostic value. These markers are essential in predicting patient outcomes and guiding personalized treatment strategies.
Furthermore, biomarkers have become integral to the therapeutic management of gynaecological cancers, aiding in decisions regarding surgery, chemotherapy, radiotherapy, immunotherapy, and targeted treatments. For instance, mutations in TP53 and BRCA1/2 can predict a tumor's response to chemotherapy and targeted therapies. The advent of next-generation sequencing (NGS) has further refined the identification of actionable mutations, facilitating personalized treatment approaches and improving clinical outcomes.
This Research Topic aims to enhance our understanding of gynaecological tumors by investigating innovative approaches in biomarker discovery, diagnosis, and treatment. The objective is to promote interdisciplinary research that can lead to significant advancements in early detection, improve prognosis prediction, and refine personalized therapeutic strategies. By focusing on the clinical and biological characteristics of these tumors, we seek to develop non-invasive or minimally invasive methods that will ultimately improve patient outcomes and inform more precise treatment decisions for gynaecological cancers and precancerous lesions.
We invite contributions that address, but are not limited to, the following themes:
o Discovery and validation of new biomarkers for early diagnosis and prevention of gynaecological tumors using various biological samples such as tissue, cells, blood, and urine.
o Investigation of the genetic, epigenetic, mRNA, proteomic, microbiological, and metabolomic characteristics of biomarkers and their role in the non-invasive or minimally invasive detection of gynecologic tumors.
o Evaluation of the prognostic and therapeutic implications of biomarkers in predicting disease progression, treatment response, and patient outcomes.
o Examination of the clinical significance of biomarkers in enhancing quality of life, optimizing health economics, reducing reproductive tract injury, and preserving fertility.
Keywords:
biomarker, gynaecological tumours, cervical cancer, endometrial cancer, ovarian cancer
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Recent advancements in the field of biomarkers have significantly enhanced the early diagnosis and prevention of gynaecological tumors, including cervical, endometrial, and ovarian cancers. These biomarkers are pivotal in the accurate, non-invasive detection of early-stage cancers, thereby facilitating timely therapeutic interventions while the disease is still manageable. Despite these strides, the diagnosis of gynaecological tumors often occurs at advanced stages, underscoring an urgent need for improved early detection methodologies.
The development and validation of new biomarker detection techniques hold promise for early identification of gynaecological malignancies, even at the precancerous stage. Early detection is crucial as it directly influences treatment efficacy and patient outcomes. Biomarkers such as hormone receptors, HER2, Ki-67, TP53, and BRCA1/BRCA2 have garnered significant research interest due to their prognostic value. These markers are essential in predicting patient outcomes and guiding personalized treatment strategies.
Furthermore, biomarkers have become integral to the therapeutic management of gynaecological cancers, aiding in decisions regarding surgery, chemotherapy, radiotherapy, immunotherapy, and targeted treatments. For instance, mutations in TP53 and BRCA1/2 can predict a tumor's response to chemotherapy and targeted therapies. The advent of next-generation sequencing (NGS) has further refined the identification of actionable mutations, facilitating personalized treatment approaches and improving clinical outcomes.
This Research Topic aims to enhance our understanding of gynaecological tumors by investigating innovative approaches in biomarker discovery, diagnosis, and treatment. The objective is to promote interdisciplinary research that can lead to significant advancements in early detection, improve prognosis prediction, and refine personalized therapeutic strategies. By focusing on the clinical and biological characteristics of these tumors, we seek to develop non-invasive or minimally invasive methods that will ultimately improve patient outcomes and inform more precise treatment decisions for gynaecological cancers and precancerous lesions.
We invite contributions that address, but are not limited to, the following themes:
o Discovery and validation of new biomarkers for early diagnosis and prevention of gynaecological tumors using various biological samples such as tissue, cells, blood, and urine.
o Investigation of the genetic, epigenetic, mRNA, proteomic, microbiological, and metabolomic characteristics of biomarkers and their role in the non-invasive or minimally invasive detection of gynecologic tumors.
o Evaluation of the prognostic and therapeutic implications of biomarkers in predicting disease progression, treatment response, and patient outcomes.
o Examination of the clinical significance of biomarkers in enhancing quality of life, optimizing health economics, reducing reproductive tract injury, and preserving fertility.
Keywords:
biomarker, gynaecological tumours, cervical cancer, endometrial cancer, ovarian cancer
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.